BTK and lymphoid leukemia: Ibrutinib is an FDA-approved B-cell lymphoma/lymphocytic leukemia agent that inhibits BTK (Bruton tyrosine kinase) activation, leading to decreased B-cell receptor signaling and decreased proliferative potential.